Congenital disorder of glycosylation Ia with deficient phosphomannomutase activity but normal plasma glycoprotein pattern.

References 1. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 1995;45:729–44. 2. Van Cangh PJ, De Nayer P, Sauvage P, Tombal B, Elsen M, Lorge F, et al. Free to total prostate-specific antigen (PSA) ratio is superior to total PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate Suppl 1996;7:30–4. 3. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542–7. 4. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5–12. 5. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices; approved guideline. NCCLS guideline EP5-A. Wayne, PA: NCCLS, February 1999. 6. National Committee for Clinical Laboratory Standards. Interference testing in clinical chemistry; proposed guideline. NCCLS guideline EP7-P. Villanova, PA: NCCLS, August 1986. 7. Woodrum DL, French C, Shamel LB. Stability of free PSA in serum samples under a variety of sample collection and sample storage conditions. Urology 1996;48(Suppl 6A):33–9. 8. Woodrum DL, York L. Two-year stability of free and total PSA in frozen serum samples. Urology 1998;52:247–51. 9. Blase AB, Sokloff RL, Smith KM. Five PSA methods compared by assaying samples with defined PSA ratios [Technical Brief]. Clin Chem 1997;43: 843–4. 10. Strobel SA, Sokoloff RL, Wolfert RL, Rittenhouse HG. Multiple forms of prostate specific antigen in serum measured differently in equimolar-and skewed-response assays [Letter]. Clin Chem 1995;41:125–7. 11. Semjonow A, Oberpenning F, Brandt B, Zechel C, Brandau W, Hertle L. Impact of free prostate-specific antigen on discordant measurement results of assay for total prostate-specific antigen. Urology 1996;48:10–5. 12. Sokoll LJ, Chan DW. Total, free, and complexed PSA: analysis and clinical utility. J Clin Ligand Assay 1998;21:171–9.